Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

被引：63

作者：

Duda, Dan G.

Willett, Christopher G. ^{[1
]}

Ancukiewicz, Marek

di Tomaso, Emmanuelle

Shah, Mira ^{[1
]}

Czito, Brian G. ^{[1
]}

Bentley, Rex ^{[2
]}

Poleski, Martin ^{[3
]}

Lauwers, Gregory Y. ^{[5
]}

Carroll, Madeline ^{[1
]}

Tyler, Douglas ^{[3
]}

Mantyh, Christopher ^{[3
]}

Shellito, Paul ^{[6
]}

Clark, Jeffrey W. ^{[7
]}

Jain, Rakesh K. ^{[4
]}

机构：

[1] Duke Univ, Dept Radiat Oncol, Med Ctr, Durham, NC 27710 USA

[2] Duke Univ, Dept Pathol, Med Ctr, Durham, NC 27710 USA

[3] Duke Univ, Dept Med & Surg, Med Ctr, Durham, NC 27710 USA

[4] Massachusetts Gen Hosp, Steele Lab, Dept Radiat Oncol, Boston, MA 02114 USA

[5] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[6] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA

[7] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA

来源：

ONCOLOGIST | 2010年 / 15卷 / 06期

关键词：

Bevacizumab; sVEGFR-1; Biomarker; Rectal cancer; Chemoradiation; Toxicity; ENDOTHELIAL GROWTH-FACTOR; THERAPY; CHEMOTHERAPY; CHEMORADIOTHERAPY; FLUOROURACIL; LEUCOVORIN; REGRESSION; RADIATION; CETUXIMAB; BIOLOGY;

D O I：

10.1634/theoncologist.2010-0029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting. The Oncologist 2010;15:577-583

引用

页码：577 / 583

页数：7

共 26 条

[1] Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy:: A longitudinal study of protein kinetics throughout tumor progression and therapy [J].